Autolus, Moderna ink license agreement

By The Science Advisory Board staff writers

August 2, 2021 -- Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding agents for four immuno-oncology targets.

Under terms of the deal, Autolus will be eligible to receive payment for each target Moderna licenses, as well as to receive milestone payments for each target that is successfully brought to market. Autolus will also receive royalties on net sales of each target.

EMA takes positive stance on Moderna COVID-19 vaccine for adolescents
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has taken a positive position on marketing authorization for Moderna's...
Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents.
Moderna, Medison partner on Moderna's COVID-19 vaccine
Moderna and Medison Pharma announced that they are entering into a marketing agreement for Moderna's COVID-19 vaccine across central Europe and Israel.
Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine.
Moderna vaccine 100% effective for teens
Moderna announced its phase II/III study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter